Trying 3106016892...Open

Welcome to STN International! Enter x:x

LOGINID:ssspta1644pnh

PASSWORD:

i in i

TERMINAL (ENTER 1, 2, 3, OR ?):2

```
* * * * * * * * *
                     Welcome to STN International
                 Web Page URLs for STN Seminar Schedule - N. America
NEWS
                 The Philippines Inventory of Chemicals and Chemical
         Sep 29
NEWS 2
                 Substances (PICCS) has been added to CHEMLIST
                 New Extraction Code PAX now available in Derwent
      3 Oct 27
NEWS
                 Files
                 SET ABBREVIATIONS and SET PLURALS extended in
      4 Oct 27
NEWS
                 Derwent World Patents Index files
                 Patent Assignee Code Dictionary now available
NEWS
      5 Oct 27
                 in Derwent Patent Files
NEWS 6 Oct 27 Plasdoc Key Serials Dictionary and Echoing added to
                 Derwent Subscriber Files WPIDS and WPIX
NEWS 7 Nov 29 Derwent announces further increase in updates for DWPI
NEWS 8 Dec 5 French Multi-Disciplinary Database PASCAL Now on STN
NEWS 9 Dec 5 Trademarks on STN - New DEMAS and EUMAS Files
NEWS 10 Dec 15 2001 STN Pricing
NEWS 11 Dec 17 Merged CEABA-VTB for chemical engineering and
                 biotechnology
                 Corrosion Abstracts on STN
NEWS 12 Dec 17
NEWS 13 Dec 17 SYNTHLINE from Prous Science now available on STN
NEWS 14 Dec 17 The CA Lexicon available in the CAPLUS and CA files
                 AIDSLINE is being removed from STN
NEWS 15 Jan 05
NEWS EXPRESS FREE UPGRADE 5.0e FOR STN EXPRESS 5.0 WITH DISCOVER!
               (WINDOWS) NOW AVAILABLE
              STN Operating Hours Plus Help Desk Availability
NEWS HOURS
              General Internet Information
NEWS INTER
              Welcome Banner and News Items
NEWS LOGIN
              Direct Dial and Telecommunication Network Access to STN
NEWS PHONE
              CAS World Wide Web Site (general information)
 NEWS WWW
```

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

FILE 'HOME' ENTERED AT 12:43:11 ON 24 JAN 2001

=> file medline embase biosis scisearch caplus

COST IN U.S. DOLLARS

FULL ESTIMATED COST

SINCE FILE TOTAL
ENTRY SESSION
0.15 0.15

FILE 'MEDLINE' ENTERED AT 12:43:32 ON 24 JAN 2001

FILE 'EMBASE' ENTERED AT 12:43:32 ON 24 JAN 2001

COPYRIGHT (C) 2001 Elsevier Science B.V. All rights reserved.

FILE 'BIOSIS' ENTERED AT 12:43:32 ON 24 JAN 2001

COPYRIGHT (C) 2001 BIOSIS(R)

FILE 'SCISEARCH' ENTERED AT 12:43:32 ON 24 JAN 2001 COPYRIGHT (C) 2001 Institute for Scientific Information (ISI) (R)

FILE 'CAPLUS' ENTERED AT 12:43:32 ON 24 JAN 2001 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT. PLEASE SEE "HELP USAGETERMS" FOR DETAILS. COPYRIGHT (C) 2001 AMERICAN CHEMICAL SOCIETY (ACS)

=> s avian antibody

L1 108 AVIAN ANTIBODY

=> s ll and Escherichia coli H7 strain

L2 0 L1 AND ESCHERICHIA COLI H7 STRAIN

=> s l1 and E coli

L3 0 L1 AND E COLI

=> s l1 and anaerobacteria

L4 0 L1 AND ANAEROBACTERIA

=> s 11 and peptostriptoccus anaerobius

L5 0 L1 AND PEPTOSTRIPTOCCUS ANAEROBIUS

=> s l1 and bacteria

L6 2 L1 AND BACTERIA

=> d 16

L6 ANSWER 1 OF 2 BIOSIS COPYRIGHT 2001 BIOSIS

AN 1998:262100 BIOSIS

DN PREV199800262100

TI Antibodies to recombinant Clostridium difficile toxins A and B are an effective treatment and prevent relapse of C. difficile-associated disease

in a hamster model of infection.

AU Kink, John A. (1); Williams, Jim A.

CS (1) Ophidian Pharmaceuticals Inc., 5445 East Cheryl Pkwy., Madison, WI 53711 USA

SO Infection and Immunity, (May, 1998) Vol. 66, No. 5, pp. 2018-2025. ISSN: 0019-9567.

DT Article

LA English

```
ANSWER 1 OF 2 BIOSIS COPYRIGHT 2001 BIOSIS
    1998:262100 BIOSIS
ΑN
DN
    PREV199800262100
    Antibodies to recombinant Clostridium difficile toxins A and B are an
    effective treatment and prevent relapse of C. difficile-associated
disease
    in a hamster model of infection.
    Kink, John A. (1); Williams, Jim A.
ΑIJ
     (1) Ophidian Pharmaceuticals Inc., 5445 East Cheryl Pkwy., Madison, WI
CS
     53711 USA
    Infection and Immunity, (May, 1998) Vol. 66, No. 5, pp. 2018-2025.
SO
    ISSN: 0019-9567.
DT
    Article
    English
T.A
    Clostridium difficile causes antibiotic-associated diarrhea and colitis
AΒ
in
    humans through the actions of toxin A and toxin B on the colonic mucosa.
    At present, broad-spectrum antibiotic drugs are used to treat this
    disease, and patients suffer from high relapse rates after termination of
     treatment. This study examined the role of both toxins in pathogenesis
and
     the ability of orally administered avian antibodies
     against recombinant epitopes of toxin A and toxin B to treat C
    difficile-associated disease (CDAD). DNA fragments representing the
entire
     gene of each toxin were cloned, expressed, and affinity purified. Hens
    were immunized with these purified recombinant-protein fragments of toxin
    A and toxin B. Toxin-neutralizing antibodies fractionated from egg yolks
    were evaluated by a toxin neutralization assay in Syrian hamsters. The
     carboxy-terminal region of each toxin was most effective in generating
     toxin-neutralizing antibodies. With a hamster infection model, antibodies
     to both toxins A and B (CDAD antitoxin) were required to prevent
morbidity
     and mortality from infection. In contrast to vancomycin, CDAD antitoxin
    prevented relapse and subsequent C. difficile reinfection in the
hamsters.
     These results indicate that CDAD antitoxin may be effective in the
     treatment and management of CDAD in humans.
CC
     Pharmacology - Immunological Processes and Allergy *22018
     Biochemical Studies - Proteins, Peptides and Amino Acids *10064
     Biochemical Studies - Carbohydrates *10068
     Toxicology - General; Methods and Experimental *22501
     Physiology and Biochemistry of Bacteria *31000
     Immunology and Immunochemistry - General; Methods *34502
     Immunology and Immunochemistry - Bacterial, Viral and Fungal *34504
    Medical and Clinical Microbiology - Bacteriology *36002
ВC
    Endospore-forming Gram-Positives
                                         07810
IT
    Major Concepts
        Immune System (Chemical Coordination and Homeostasis); Pharmacology
TΤ
     Chemicals & Biochemicals
        anti-Clostridium difficile toxin A antibody: immunostimulant - drug;
        anti-Clostridium difficile toxin B antibody: immunostimulant - drug;
```

recombinant Clostridium difficile toxin A; recombinant Clostridium

```
difficile toxin B
TΥ
    Methods & Equipment
        in vitro toxin neutralization assay
ORGN Super Taxa
        Endospore-forming Gram-Positives: Eubacteria, Bacteria,
        Microorganisms
ORGN Organism Name
        Clostridium-difficile (Endospore-forming Gram-Positives): pathogen
ORGN Organism Superterms
        Bacteria; Eubacteria; Microorganisms
L6
     ANSWER 2 OF 2 CAPLUS COPYRIGHT 2001 ACS
ΑN
     1998:635674 CAPLUS
     129:259335
DN
ΤI
    Use of avian antibodies
    Larsson, Anders; Kollberg, Hans
IN
PΑ
     Immunsystem Ims AB, Swed.
SO
     PCT Int. Appl., 16 pp.
    CODEN: PIXXD2
DT
    Patent
LA
    English
IC
     ICM A61K039-40
     ICS C07K016-02
CC
     15-3 (Immunochemistry)
FAN.CNT 1
    PATENT NO.
                     KIND DATE
                                         APPLICATION NO. DATE
     _____
                     ~---
                                          _____
                           19980924
                                         WO 1998-SE526
                                                           19980320
PT
    WO 9841235
                     A1
        W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE,
            DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG,
            KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX,
            NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT,
            UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
         RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI,
             FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM,
             GA, GN, ML, MR, NE, SN, TD, TG
                                          SE 1997-1212
     SE 9701212
                           19980921
                                                           19970403
                      Α
     SE 511993
                      C2
                           20000110
    AU 9865312
                      A1
                           19981012
                                          AU 1998-65312
                                                           19980320
    EP 971741
                           20000119
                                          EP 1998-911344
                                                           19980320
                      A1
            AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
            IE, FI
    BR 9808392
                      Α
                           20000523
                                         BR 1998-8392
                                                           19980320
PRAI SE 1997-1026
                     19970320
    WO 1998-SE526
                     19980320
    The present invention relates to use of avian antibodies
     and/or antigen binding fragments thereof, for the prodn. of a drug for
     treatment and/or prevention of respiratory tract infections. The
     infection is bacterial, viral or fungal. The drug is administered
through
     local application at the oral cavity and/or pharynx. Antibodies against
     Pseudomonas aeruginosa was prepd. in and purified from domestic hens for
    treating Pseudomonas infection.
    avian antibody respiratory tract infection
    Bacterial infection
    Bird (Aves)
    Lymph
    Mouthwashes
```

```
Oral drug delivery systems
     Pharynx
     Pseudomonas
     Pseudomonas aeruginosa
     Pulmonary infection
     Respiratory tract infection
     Viral infection
        (avian antibodies for treating respiratory tract
        infection by bacteria or virus or fungus)
ΙT
     Antibodies
     RL: BPN (Biosynthetic preparation); PUR (Purification or recovery); THU
     (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
     (Uses)
        (avian antibodies for treating respiratory tract
        infection by bacteria or virus or fungus)
TТ
     Antiqens
     RL: BSU (Biological study, unclassified); BIOL (Biological study)
        (avian antibodies for treating respiratory tract
        infection by bacteria or virus or fungus)
IT
     Chicken (Gallus domesticus)
        (domestic hens; avian antibodies for treating
        respiratory tract infection by bacteria or virus or fungus)
IT
     Bronchial diseases
        (infection; avian antibodies for treating
        respiratory tract infection by bacteria or virus or fungus)
IT
     Pharynx
        (oropharynx; avian antibodies for treating
        respiratory tract infection by bacteria or virus or fungus)
=> d his
     (FILE 'HOME' ENTERED AT 12:43:11 ON 24 JAN 2001)
     FILE 'MEDLINE, EMBASE, BIOSIS, SCISEARCH, CAPLUS' ENTERED AT 12:43:32 ON
     24 JAN 2001
            108 S AVIAN ANTIBODY
L1
L2
              O S L1 AND ESCHERICHIA COLI H7 STRAIN
L3
              0 S L1 AND E COLI
T.4
              0 S L1 AND ANAEROBACTERIA
L5
              O S L1 AND PEPTOSTRIPTOCCUS ANAEROBIUS
L6
              2 S L1 AND BACTERIA
=> s 11 and ruminal bacteria
             0 L1 AND RUMINAL BACTERIA
L7
=> s E coli H7
            17 E COLI H7
1.8
=> dup remove 18
PROCESSING COMPLETED FOR L8
              6 DUP REMOVE L8 (11 DUPLICATES REMOVED)
```

Mycosis

ANSWER 1 OF 6 CAPLUS COPYRIGHT 2001 ACS

L9

```
1998:207285 CAPLUS
ΑN
DN
    128:228232
TΙ
    Motility channel pathogen detector and method of use
    Wun, Chun Kwun; Torre, Frank J.
ΙN
PA
    Springfield College, USA
SO
    U.S., 9 pp.
    CODEN: USXXAM
DT
    Patent
LA
    English
    ICM G01N033-567
IC
NCL
    435007210
CC
    9-1 (Biochemical Methods)
FAN.CNT 1
     PATENT NO.
                     KIND DATE
                                         APPLICATION NO. DATE
     ------
                     ____
                           _____
                                          ______
ΡI
    US 5733736
                    A
                           19980331
                                          US 1996-767165
                                                           19961216
                                          WO 1997-U$14156 19970827
    WO 9827431
                     A1
                           19980625
            AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE,
            DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ,
            LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL,
            PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ,
            VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
        RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR,
            GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA,
            GN, ML, MR, NE, SN, TD, TG
     AU 9742299
                     A1
                           19980715
                                          AU 1997-42299
                                                           19970827
     EP 956505
                      A1
                           19991117
                                          EP 1997-940548
                                                           19970827
        R: CH, DE, FR, GB, LI, NL
PRAI US 1996-767165
                     19961216
    WO 1997-US14156 19970827
    A motility channel pathogen detector and method of use of the detector
AB
are
    disclosed for detecting a target motile pathogen in a test sample of
    potential pathogens. The motility channel pathogen detector includes: a
    dish having a base and walls arising from the base to define a motility
    channel; an anti-serum end of the motility channel; an inoculation end of
     the motility channel opposed to the anti-serum end; and opposed channel
    walls that cooperate to define the motility channel between the
anti-serum
    and inoculation ends of the channel. A growth medium is positioned in
the
    motility channel and an anti-serum that biol. interacts with the target
    motile pathogen is positioned in the growth medium in the anti-serum end
    so that the anti-serum diffuses in the growth medium to form an
anti-serum
    front between the channel walls. The sample of potential pathogens is
     inoculated in the growth medium adjacent the inoculation end so that any
     target motile pathogen moves towards, contacts and accumulates at the
    anti-serum front to form a visible detection line adjacent the anti-serum
     front. In one embodiment the target motile pathogen is a serotype of
    Escherichia coli bacteria generally known as "E. coli 0157:H7", and the
    anti-serum is E. coli H7 anti-serum which
    restricts motility of the pathogen.
    motility channel pathogen detector
```

IТ Peptones RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses) (Proteose; motility channel pathogen detector and method of use) Antiserums IT Culture media Escherichia coli Pathogenic microorganism Sensors (motility channel pathogen detector and method of use) 60-00-4, Edta, biological studies 56-45-1, L-Serine, biological studies IT 302-95-4, Sodium deoxycholate 63-68-3, L-Methionine, biological studies 7487-88-9, Magnesium sulfate, biological studies 7790-58-1, Potassium 9002-18-0, Agar 16068-46-5, Potassium phosphate tellurite RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses) (motility channel pathogen detector and method of use) DUPLICATE 1 ANSWER 2 OF 6 MEDLINE Ь9 MEDLINE ΑN 97193822 97193822 DN Use of the flagellar H7 gene as a target in multiplex PCR assays and TΙ improved specificity in identification of enterohemorrhagic Escherichia coli strains. Gannon V P; D'Souza S; Graham T; King R K; Rahn K; Read S ΑU Animal Diseases Research Institute, Agriculture and Agri-Food Canada, ÇS Lethbridge, Alberta, Canada.. gannonv@em.agr.ca JOURNAL OF CLINICAL MICROBIOLOGY, (1997 Mar) 35 (3) 656-62. SO Journal code: HSH. ISSN: 0095-1137. United States CY Journal; Article; (JOURNAL ARTICLE) DTLAEnglish Priority Journals FS GENBANK-L07338; GENBANK-U47614 os EM 199708 19970801 EW PCR products of 1.8 kb were generated with DNAs from all Escherichia coli AB H7 strains tested by using oligonucleotide primers which flank the fliC gene. Three RsaI digestion profiles of these PCR products were evident on agarose gels; the first occurred with serotype O55:H7, O157:H7, or nonmotile (NM) strains, the second occurred with serotype O1:H7 and O18:H7 strains, and the third occurred with serotype O?:H7, O19:H7, O121:H7, 088:H7, and 0156:H7 strains. Despite these differences, the nucleotide sequences of the E. coli E32511 (O157:NM) and U5-41 (O1:H7) flic genes were 97% homologous. Two PCR primer pairs synthesized on the basis of the E32511 H7 flic sequence amplified specific DNA fragments from all E. coli H7 strains, but did not amplify DNA fragments from the other bacterial strains. The H7-specific primers were used in combination with other primers which target the Verotoxin 1(VT1) and VT2 genes and the E. coli O157:H7 eaeA gene in multiplex PCR assays. In these assays, vt and eaeA PCR products were observed with DNAs from

the

majority of EHEC strains and vt, eaeA, and flic PCR products were observed

with DNAs from E. coli O157:H7 or NM strains. Only eaeA PCR products were present with DNA from enteropathogenic E. coli, and only vt PCR products occurred with VT-producing E. coli which are not EHEC. The multiplex PCR

```
assays described allow for the specific identification of E. coli O157:H7
     or NM and other EHEC strains.
CT
     Check Tags: Animal; Human; Support, Non-U.S. Gov't
      Bacterial Outer Membrane Proteins: GE, genetics
      Bacterial Toxins: GE, genetics
      Base Sequence
      DNA Primers: GE, genetics
      DNA, Bacterial: GE, genetics
      Escherichia coli: CL, classification
     *Escherichia coli: GE, genetics
      Escherichia coli: IP, isolation & purification
      Escherichia coli Infections: MI, microbiology
      Escherichia coli 0157: CL, classification
      Escherichia coli O157: GE, genetics
      Escherichia coli 0157: IP, isolation & purification
     *Flagella: GE, genetics
      Flagellin: GE, genetics
     *Genes, Bacterial
      Molecular Sequence Data
     *Polymerase Chain Reaction: MT, methods
      Polymerase Chain Reaction: SN, statistics & numerical data
      Sensitivity and Specificity
      Sequence Homology, Nucleic Acid
      Serotyping
RN
     12777-81-0 (Flagellin); 147094-99-3 (eae protein); 156066-56-7 (FlaC
     protein)
     0 (Bacterial Outer Membrane Proteins); 0 (Bacterial Toxins); 0 (DNA
CN
     Primers); 0 (DNA, Bacterial); 0 (Shiga-like toxin I); 0 (Shiga-like toxin
L9
     ANSWER 3 OF 6 MEDLINE
                                                         DUPLICATE 2
ΑN
     97335329
                 MEDLINE
DN
     97335329
     Variation in manifestation of E. coli H7
TΙ
     antigen.
ΑU
     Bailey C W; Carson C A
CS
     WHO Collaborating Center for Enteric Zoonoses, College of Veterinary
     Medicine, University of Missouri, Columbia 65211, USA.
SO
     ADVANCES IN EXPERIMENTAL MEDICINE AND BIOLOGY, (1997) 412 83-5.
     Journal code: 2LU. ISSN: 0065-2598.
CY
     United States
     Journal; Article; (JOURNAL ARTICLE)
DT
LA
     English
     Priority Journals
FS
     199710
FM
F.W
     19971005
     Check Tags: Support, Non-U.S. Gov't
CT
      DNA Primers
     *Escherichia coli O157: GE, genetics
      Escherichia coli 0157: IM, immunology
     *Flagellin: GE, genetics
      Flagellin: IM, immunology
      Genes, Structural, Bacterial
      Polymerase Chain Reaction: MT, methods
RN
     12777-81-0 (Flagellin); 156066-56-7 (FlaC protein)
CN
     0 (DNA Primers)
L9
    ANSWER 4 OF 6 MEDLINE
                                                         DUPLICATE 3
```

```
96387752
                 MEDLINE
ΑN
    96387752
DN
    Monoclonal antibodies for detection of the H7 antigen of Escherichia
ΤI
coli.
    He Y; Keen J E; Westerman R B; Littledike E T; Kwang J
ΑU
     U.S. Meat Animal Research Center, U.S. Department of Agriculture, Clay
CS
     Center, Nebraska 68933, USA.. he@aux.marc.usda.gov
    APPLIED AND ENVIRONMENTAL MICROBIOLOGY, (1996 Sep) 62 (9) 3325-32.
SO
     Journal code: 6K6. ISSN: 0099-2240.
CY
    United States
     Journal; Article; (JOURNAL ARTICLE)
DT
LA
     English
     Priority Journals
FS
     199612
EM
     Two murine monoclonal antibodies (MAbs) (2B7 and 46E9-9) reactive with
AB
the
     H7 flagellar antigen of Escherichia coli were produced and characterized.
     A total of 217 E. coli strains (48 0157:H7, 4 0157:NM, 23 0157:non-H7, 22
    H7:non-O157, and 120 non-O157:nonH7), 17 Salmonella serovars, and 29
other
     gram-negative bacteria were used to evaluate the reactivities of the two
     MAbs by indirect enzyme-linked immunosorbent assay (ELISA). Both MAbs
     reacted strongly with all E. coli strains possessing the H7 antigen and
     with H23- and H24-positive E. coli strains. Indirect ELISA MAb
     was confirmed by inhibition ELISA and by Western blotting
     (immunoblotting), using partially purified flagellins from E. coli
     and other E. coli strains. On a Western blot, MAb 46E9-9 was more
reactive
     against H7 flagellin of E. coli O157:H7 than against H7 flagellin of E.
     coli O1:K1:H7. Competition ELISA suggested that MAbs 2B7 and 46E9-9
     reacted with closely related H7 epitopes. When the ELISA reactivities of
     the MAbs and two commercially available polyclonal anti-H7 antisera were
     compared, both polyclonal antisera and MAbs reacted strongly with
     E. coli H7 bacteria. However, the polyclonal
     antisera cross-reacted strongly both with non-H7 E. coli and with many
     non-E. coli bacteria. The polyclonal antisera also reacted strongly with
     H23 and H24 E. coli isolates. The data suggest the need to define
     serotype-specific epitopes among H7, H23, and H24 E. coli flagella. The
     anti-H7 MAbs described in this report have the potential to serve as
     high-quality diagnostic reagents, used either alone or in combination
     O157-specific MAbs, to identify or detect E. coli O157:H7 in food
products
     or in human and veterinary clinical specimens.
     Check Tags: Animal
     *Antibodies, Monoclonal: IM, immunology
      Antibody Specificity
     *Antigens, Bacterial: AN, analysis
      Cross Reactions
      Enzyme-Linked Immunosorbent Assay
     *Escherichia coli: IM, immunology
      Mice
      Mice, Inbred BALB C
      Serotyping
     O (Antibodies, Monoclonal); O (Antigens, Bacterial)
CN
```

```
86086289
                 MEDLINE
AN
DN
     86086289
TT
     H7 antiserum-sorbitol fermentation medium: a single tube screening medium
     for detecting Escherichia coli O157:H7 associated with hemorrhagic
     colitis.
ΑU
     Farmer J J 3d; Davis B R
     JOURNAL OF CLINICAL MICROBIOLOGY, (1985 Oct) 22 (4) 620-5.
SO
     Journal code: HSH. ISSN: 0095-1137.
CY
     United States
DT
     Journal; Article; (JOURNAL ARTICLE)
LΑ
     English
FS
     Priority Journals
EM
     198604
AB
     Escherichia coli serotype 0157:H7 has been isolated from outbreaks and
     sporadic cases of hemorrhagic colitis. There is convincing evidence that
     it can cause this diarrheal disease. Because of the interest in
     hemorrhagic colitis, it has become desirable to detect this particular
     strain in human feces, which usually contains many other strains of E.
     coli. Two characteristics of the incriminated E. coli O157:H7 strain have
     made its isolation and identification easier. It does not ferment
     D-sorbitol rapidly, in contrast to about 95% of other E. coli strains. In
     addition, the strain has H antigen 7, but only about 10% of other E. coli
     strains have this particular antigen. To screen for E. coli O157:H7 we
     devised H7 antiserum-sorbitol fermentation medium (18 g of enteric
     fermentation base, 10 g of D-sorbitol, 4 g of agar, 10 ml of Andrade
     indicator, 989 ml of water; all ingredients were mixed, autoclaved, and
     cooled; 1 ml of E. coli H7 antiserum was
     then added). Colonies to be screened were inoculated into this medium.
     Strains of E. coli O157:H7 gave a characteristic pattern; they did not
     ferment sorbitol and were immobilized in the semisolid medium because of
     the reaction of their flagella with the flagella antiserum. Almost all
     other strains of E. coli gave a different pattern; they fermented
sorbitol
     or were not immobilized by the H7 serum or both. Strains which were
     presumptive positives (sorbitol negative, H7 positive) were then tested
in
     E. coli O157 serum by slide or tube agglutination. (ABSTRACT TRUNCATED AT
     250 WORDS)
CT
     Check Tags: Human
     Agglutination Tests
     *Antigens, Bacterial: AN, analysis
     Antigens, Bacterial: IM, immunology
     *Colitis: MI, microbiology
      Culture Media
     Escherichia coli: IM, immunology
     *Escherichia coli: IP, isolation & purification
     Escherichia coli: ME, metabolism
     *Escherichia coli Infections: MI, microbiology
      False Positive Reactions
     *Feces: MI, microbiology
      Fermentation
      Flagella: IM, immunology
     *Gastrointestinal Hemorrhage: MI, microbiology
      Immune Sera
     *Sorbitol: ME, metabolism
      Species Specificity
     50-70-4 (Sorbitol)
RN
                                                                        Page 10
```

DUPLICATE 4

L9

ANSWER 5 OF 6 MEDLINE

```
CN 0 (Antigens, Bacterial); 0 (Culture Media); 0 (H antigen)
```

- L9 ANSWER 6 OF 6 EMBASE COPYRIGHT 2001 ELSEVIER SCI. B.V.
- AN 85238836 EMBASE
- DN 1985238836
- TI H7 antiserum-sorbitol fermentation medium: A single tube screening medium for detecting Escherichia coli O157:H7 associated with hemorrhagic colitis.
- AU Farmer III J.J.; Davis B.R.
- CS Enteric Bacteriology Section, Center for Infectious Diseases, Centers for Disease Control, Atlanta, GA 30333, United States
- SO Journal of Clinical Microbiology, (1985) 22/4 (620-625). CODEN: JCMIDW
- CY United States
- DT Journal
- FS 004 Microbiology
  - 026 Immunology, Serology and Transplantation
  - 048 Gastroenterology
- LA English
- Escherichia coli serotype O157:H7 has been isolated from outbreaks and AB sporadic cases of hemorrhagic colitis. There is convincing evidence that it can cause this diarrheal disease. Because of the interest in hemorrhagic colitis, it has become desirable to detect this particular strain in human feces, which usually contains many other strains of E. coli. Two characteristics of the incriminated E. coli 0157:H7 strain have made its isolation and identification easier. It does not ferment D-sorbitol rapidly, in contrast to about 95% of other E. coli strains. In addition, the strain has H antigen 7, but only about 10% of other E. coli strains have this particular antigen. To screen for E. coli O157:H7 we devised H7 antiserum-sorbitol fermentation medium (18 g of enteric fermentation base, 10 g of D-sorbitol, 4 g of agar, 10 ml of Andrade indicator, 989 ml of water; all ingredients were mixed, autoclaved, and cooled; 1 ml of E. coli H7 antiserum was then added). Colonies to be screened were inoculated into this medium. Strains of E. coli O157:H7 gave a characteristic pattern; they did not ferment sorbitol and were immobilized in the semisolid medium because of the reaction of their flagella with the flagella antiserum. Almost all other strains of E. coli gave a different pattern; they fermented sorbitol

or were not immobilized by the H7 serum or both. Strains which were presumptive positives (sorbitol negative, H7 positive) were then tested

E. coli O157 serum by slide or tube agglutination. The number of strains which were presumptive positive by H7-sorbitol medium but then were not found to be O157 was less than 1%. A second approach has been helpful in deciding which colonies to screen in H7-sorbitol medium.

MacConkey-sorbitol agar (22.2 g of MacConkey agar base [which contains no sugar], 10 g of D-sorbitol, 1,000 ml of water) was designed as a plating medium. Stools were plated on MacConkey agar to estimate the number of E.

coli colonies and also plated on MacConkey-sorbitol agar to estimate the number of sorbitol-negative colonies of E. coli. These two approaches

have

proved useful for isolating and identifying E. coli O157:H7 from human feces and from feces of animals infected in the laboratory with this strain. The results suggest that media may be formulated in a similar fashion for detecting other specific strains of E. coli.

CT Medical Descriptors: \*escherichia coli

```
*fermentation
     *h antigen
     *ulcerative colitis
     culture medium
     feces
    food
    large intestine
    priority journal
    diagnosis
    in vitro study
    nonhuman
    digestive system
    Drug Descriptors:
     *sorbitol
     shiga toxin
     (sorbitol) 26566-34-7, 50-70-4, 53469-19-5; (shiga toxin) 75757-64-1
RN
=> s P anaerobius
           204 P ANAEROBIUS
T.10
=> dup remove 110
PROCESSING COMPLETED FOR L10
             91 DUP REMOVE L10 (113 DUPLICATES REMOVED)
T.11
=> s 111 and cattle
             3 L11 AND CATTLE
L12
=> d 112 all 1-3
L12 ANSWER 1 OF 3 MEDLINE
    97076913 MEDLINE
ΜA
     97076913
DN
    An rRNA approach for assessing the role of obligate amino acid-fermenting
ΤI
    bacteria in ruminal amino acid deamination.
ΑU
    Krause D O; Russell J B
CS
    Section of Microbiology, Cornell University, Ithaca, New York 14853,
USA.
    APPLIED AND ENVIRONMENTAL MICROBIOLOGY, (1996 Mar) 62 (3) 815-21.
SO
    Journal code: 6K6. ISSN: 0099-2240.
CY
    United States
    Journal; Article; (JOURNAL ARTICLE)
DT
    English
LA
FS
    Priority Journals
    199703
EΜ
    19970301
EW
    Ruminal amino acid degradation is a nutritionally wasteful process that
AΒ
    produces excess ruminal ammonia. Monensin inhibited the growth of
    monensin-sensitive, obligate amino acid-fermenting bacteria and decreased
     the ruminal ammonia concentrations of cattle. 16S rRNA probes
     indicated that monensin inhibited the growth of Peptostreptococcus
     anaerobius and Clostridium sticklandii in the rumen. Clostridium
     aminophilum was monensin sensitive in vitro, but C. aminophilum persisted
     in the rumen after monensin was added to the diet. An in vitro culture
                                                                        Page 12
```

```
system was developed to assess the competition of C. aminophilum,
     P. anaerobius, and C. sticklandii with predominant
     ruminal bacteria (PRB). PRB were isolated from a 10(8) dilution of
ruminal
     fluid and maintained as a mixed population with a mixture of
     carbohydrates. PRB did not hybridize with the probes to C. aminophilum,
     P. anaerobius, or C. sticklandii. PRB deaminated
     Trypticase in continuous culture, but the addition of C. aminophilum,
     P. anaerobius, and C. sticklandii caused a
     more-than-twofold increase in the steady-state concentration of ammonia.
     C. aminophilum, P. anaerobius, and C. sticklandii accounted for less than 5% of the total 16S rRNA and microbial protein.
     Monensin eliminated P. anaerobius and C. sticklandii
     from continuous cultures, but it could not inhibit C. aminophilum. The monensin resistance of C. aminophilum was a growth rate-dependent,
     inoculum size-independent phenomenon that could not be maintained in
batch
     culture. On the basis of these results, we concluded that the feed
     additive monensin cannot entirely counteract the wasteful amino acid
     deamination of obligate amino acid-fermenting ruminal bacteria.
     Check Tags: Animal; Female; Support, Non-U.S. Gov't
CT
     *Amino Acids: ME, metabolism
      Clostridium: IP, isolation & purification
     *Clostridium: ME, metabolism
      Deamination
      Fermentation
      Monensin: PD, pharmacology
      Peptostreptococcus: IP, isolation & purification
     *Peptostreptococcus: ME, metabolism
      Rumen: ME, metabolism
     *Rumen: MI, microbiology
      RNA Probes
     *RNA, Ribosomal, 16S
     17090-79-8 (Monensin)
RN
     0 (Amino Acids); 0 (RNA Probes); 0 (RNA, Ribosomal, 16S)
CN
L12 ANSWER 2 OF 3 MEDLINE
                  MEDLINE
ΑN
     93152452
DN
     93152452
     Phylogeny of the ammonia-producing ruminal bacteria Peptostreptococcus
     anaerobius, Clostridium sticklandii, and Clostridium aminophilum sp. nov.
     Paster B J; Russell J B; Yang C M; Chow J M; Woese C R; Tanner R
ΑU
     Forsyth Dental Center, Boston, Massachusetts 02115.
CS
NC
     DE-04881 (NIDCR)
     DE-08303 (NIDCR)
     INTERNATIONAL JOURNAL OF SYSTEMATIC BACTERIOLOGY, (1993 Jan) 43 (1)
SO
     107-10.
     Journal code: AWO. ISSN: 0020-7713.
     United States
CY
     Journal; Article; (JOURNAL ARTICLE)
DT
LΑ
     English
FS
     Priority Journals
     GENBANK-L04166; GENBANK-L04168; GENBANK-L04167; GENBANK-M59107;
     GENBANK-M59084; GENBANK-M23927; GENBANK-M26494; GENBANK-M59090;
     GENBANK-M59083; GENBANK-M23929; GENBANK-M59095
EΜ
     199305
     In previous studies, gram-positive bacteria which grew rapidly with
```

peptides or an amino acid as the sole energy source were isolated from bovine rumina. Three isolates, strains C, FT (T = type strain), and SR, were considered to be ecologically important since they produced up to 20-fold more ammonia than other ammonia-producing ruminal bacteria. On basis of phenotypic criteria, the taxonomic position of these new isolates was uncertain. In this study, the 16S rRNA sequences of these isolates and related bacteria were determined to establish the phylogenetic positions of the organisms. The sequences of strains C, FT, and SR and reference strains of Peptostreptococcus anaerobius, Clostridium sticklandii, Clostridium coccoides, Clostridium aminovalericum, Acetomaculum ruminis, Clostridium leptum, Clostridium lituseburense, Clostridium acidiurici, and Clostridium barkeri were determined by using a modified Sanger dideoxy chain termination method. Strain C, a large coccus purported to belong to the genus Peptostreptococcus, was closely related to P. anaerobius, with a level of sequence similarity of 99.6%. Strain SR, a heat-resistant, short, rod-shaped organism, was closely related to C. sticklandii, with a level of sequence similarity of 99.9%. However, strain FT, a heat-resistant, pleomorphic, rod-shaped organism, was only distantly related to some clostridial species and P. anaerobius. On the basis of the sequence data, it was clear that strain FT warranted designation as a separate species. The closest known relative of strain FT was C. coccoides (level of similarity, only 90.6%). Additional strains that are phenotypically similar to strain FT were isolated in this study. (ABSTRACT TRUNCATED AT 250 WORDS) Check Tags: Animal; Comparative Study; Female; Support, Non-U.S. Gov't; CTSupport, U.S. Gov't, Non-P.H.S.; Support, U.S. Gov't, P.H.S. \*Ammonia: ME, metabolism Cattle \*Clostridium: CL, classification Clostridium: IP, isolation & purification \*Clostridium: ME, metabolism Molecular Sequence Data \*Peptostreptococcus: CL, classification Peptostreptococcus: IP, isolation & purification \*Peptostreptococcus: ME, metabolism Phylogeny \*Rumen: MI, microbiology 7664-41-7 (Ammonia) RN L12 ANSWER 3 OF 3 BIOSIS COPYRIGHT 2001 BIOSIS 2000:450419 BIOSIS ΑN PREV200000450419 DN The isolation, characterization and enumeration of hyper-ammonia TIproducing ruminal bacteria.

AU Russell, J. B. (1); Rychlik, J. L.

CS (1) Department of Microbiology, Cornell University, Ithaca, NY, 14853 USA

SO Asian-Australasian Journal of Animal Sciences, (July, 2000) Vol. 13, No. Special Issue, pp. 121-127. print. ISSN: 1011-2367.

DT Article

LA English

SL English

AB Ruminal amino acid deamination is a wasteful process that often produces

more ammonia than bacteria can utilize. Some carbohydrate-fermenting ruminal bacteria can deaminate amino acids, but these species have specific activities of ammonia production that are lower than mixed ruminal bacteria. In the 1980's and 1990's, bacteria that could not utilize carbohydrates were isolated from the rumen, and these bacteria could deaminate amino acids at a very rapid rate and grow rapidly on peptides and amino acids. Based on 16S RNA sequences, the American isolates were identified as Peptostreptococcus anaerobius, Clostridium sticklandii, and Clostridium aminophilum. New Zealand workers recently isolated a bacterium phylogenetically similar to P.

anaerobius, but other isolates were more closely related to
Peptostreptococcus asaccharolyticus, Eubacterium nodatum and
Fusobacterium

necrophorum. Mixed ruminal bacteria from cattle fed grain produced ammonia half as fast as bacteria from cattle fed hay, and a mathematical model predicted that grain-fed cattle would have fewer hyper-ammonia producing bacteria than hay-fed cattle. When mixed bacteria from cattle fed hay were incubated at acidic pH, the ammonia production decreased, and some hyper-ammonia producing bacteria are sensitive to acidic pH. Most hyper-ammonia producing

are monensin sensitive, and monensin decreased the ruminal ammonia concentration of **cattle** fed hay. However, C. aminophilum grows with relatively high concentrations of monensin in vitro, and 16S rRNA probes indicated that monensin (350 mg/day) did not eliminate this bacterium from the rumen. Hyper-ammonia-producing bacteria are nutritionally detrimental, and additional avenues are needed to decrease their numbers in the rumen.

their numbers in the rumen.

CC Animal Production - Feeds and Feeding \*26504
Biochemical Studies - General \*10060
Biochemical Studies - Proteins, Peptides and Amino Acids \*10064
Biochemical Studies - Carbohydrates \*10068
Metabolism - General Metabolism; Metabolic Pathways \*13002
Nutrition - General Studies, Nutritional Status and Methods \*13202
Digestive System - Physiology and Biochemistry \*14004
Reproductive System - Physiology and Biochemistry \*16504
Animal Production - General; Methods \*26502
Animal Production - Breeds and Breeding \*26506
Physiology and Biochemistry of Bacteria \*31000
BC Bacteria - General Unspecified 05000

Bacteroidaceae 06901 Gram-Positive Cocci 07700 Endospore-forming Gram-Positives 07810 Irregular Nonsporing Gram-Positive Rods 08890

IT Major Concepts

Animal Husbandry (Agriculture); Metabolism; Nutrition

IT Parts, Structures, & Systems of Organisms

rumen: digestive system

IT Chemicals & Biochemicals

16S RNA; 16S rRNA probe; amino acids: deamination; ammonia: production;

carbohydrate: fermentation; monensin; peptides

IT Methods & Equipment

16S RNA sequencing: analytical method, molecular genetics method; hyper-ammonia bacteria production model: mathematical model

IT Miscellaneous Descriptors

grain: animal feed; hay: animal feed; pH
ORGN Super Taxa

Artiodactyla: Mammalia, Vertebrata, Chordata, Animalia; Bacteria: Microorganisms; Bacteroidaceae: Anaerobic Gram-Negative Rods, Eubacteria, Bacteria, Microorganisms; Endospore-forming

## Gram-Positives:

Eubacteria, Bacteria, Microorganisms; Gram-Positive Cocci: Eubacteria, Bacteria, Microorganisms; Irregular Nonsporing Gram-Positive Rods: Actinomycetes and Related Organisms, Eubacteria, Bacteria, Microorganisms

## ORGN Organism Name

 ${\tt Clostridium\ aminophilum\ (Endospore-forming\ Gram-Positives);} \\ {\tt Clostridium\ }$ 

sticklandii (Endospore-forming Gram-Positives); Eubacterium nodatum
(Irregular Nonsporing Gram-Positive Rods); Fusobacterium necrophorum
(Bacteroidaceae); Peptostreptococcus anaerobius (Gram-Positive Cocci);
Peptostreptococcus asaccharolyticus (Gram-Positive Cocci);

hyper-ammonia producing bacteria (Bacteria); ruminant (Artiodactyla) ORGN Organism Superterms

Animals; Artiodactyls; Bacteria; Chordates; Eubacteria; Mammals; Microorganisms; Nonhuman Mammals; Nonhuman Vertebrates; Vertebrates RN 7664-41-7 (AMMONIA) 17090-79-8 (MONENSIN)

=>

---Logging off of STN---

=>

Executing the logoff script...

=> LOG Y

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	52.36	52.51
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-1.18	-1.18

STN INTERNATIONAL LOGOFF AT 12:50:47 ON 24 JAN 2001